AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02305992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block with 0.2% Ropivicaine
Description: A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
Study NCT02305992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infiltration with 0.25% Bupivicaine
Description: Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
Study NCT01715116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced ICD programming
Description: * VT monitor: > 166/min~* fVT: > 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~* VF: > 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~* SVT/VT discrimination is turned on, high rate time out is OFF~* SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~* SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~* T wave-oversensing and lead noise discrimination is turned on in all devices.
Study NCT02759133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal wire
Description: Localization technique for breast surgery using metal wire
Study NCT02759133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioactive Iodine Seed
Description: Localization technique for breast surgery using Radioactive Iodine Seed
Study NCT01172392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha-2a
Description: 180 mcg / wk / SC from D0 to W48
Study NCT01172392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleotidic or Nucleosidic Treatment
Description: Analog treatment according to investigators practice
Study NCT03903783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Patients with C3G antibiotic therapy will receive cefotaxime. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed.
Study NCT01877694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auriclosene Solution 0.3%
Description: Ophthalmic solution dispensed as drops onto the eye
Study NCT01877694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Auriclosene Vehicle
Description: Ophthalmic Vehicle solution dispensed as drops onto the eye
Study NCT00914979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioSculpt
Description: The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
Study NCT01672047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: 25（OH）D level \<12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， >116.75nmol/L stopped.
Study NCT01897623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound of aorta
Study NCT03255291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Recording - Exercise
Description: Participants imagine themselves improving exercise
Study NCT03255291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: -Reminders to practice mental imagery
Study NCT03255291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Survey
Description: -Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.
Study NCT05264090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
Study NCT05264090 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
Study NCT05264090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
Study NCT03903783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Patients with C3G antibiotic therapy will receive ceftriaxone. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed.
Study NCT03064750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor exercises
Description: In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
Study NCT03064750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: patients wait as usual until surgery without special treatment.
Study NCT05325060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetically navigated total knee arthroplasty
Description: The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
Study NCT05325060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional total knee arthroplasty
Description: The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
Study NCT02898805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02898805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02117401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
Study NCT02898805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed Diet
Study NCT02898805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescribed Diet
Study NCT02898805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LopiGLIK®
Study NCT02898805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Armolipid Plus
Study NCT03069781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-estradiol
Description: 1mg/day for 3-days and 3mg/day for 7-days of Estrance
Study NCT03069781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polycose
Description: 400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
Study NCT00929591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT05264090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Description: The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
Study NCT05264090 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Combined aerobic-resistance exercise
Description: Combined aerobic-resistance exercise (group 2) was scheduled twice weekly in the form of 60-minute workouts with a load intensity at the level of sub-maximum heart frequency (75-85% SFmax). The minimum time span between the workouts was 24 hours. The workout consisted of a 10-minute warm-up, 25 minutes of aerobic exercise (spinning bicycle or bicycle ergometer), 15 minutes of resistance exercise on gym machines (bench press, leg extension and pull down) with 40-50% 1-RM (one repetition maximum) intensity (3 series of 10 exercises), and a 10-minute cool-down (stretching of the main muscle groups).
Study NCT05264090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The cardiovascular exercise
Description: The cardiovascular exercise (group 4) took the form of sixty-minute workouts scheduled two to three times weekly. The nature of the workouts was similar, combined aerobic-resistance exercise (a 10-minute warm-up, aerobic endurance on bicycle ergo meter for 25 minutes, resistance exercise on multifunctional gym machines for 15 minutes, and a 10-minute cool-down). The workout intensity was set at the level of the first ventilation threshold (VAT-1), corresponding to the following workout parameters: load (W) and heart rate (HR).19,20 The resistance exercise intensity was specified by the 1-RM (one repetition maximum) method. The maximum load lifted across the full range of motion for every exercise was used as the benchmark for the workload intensity specification, corresponding to 30 - 60% 1-RM.
Study NCT00088634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: 80 mg AM dosing once daily
Study NCT00088634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to 40mg lurasidone tablets
Study NCT03220048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP-001
Study NCT03220048 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Comparator
Study NCT03220048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Study NCT04676750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: yoga, meditation and psycho education
Study NCT01395589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
Study NCT01338103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
Study NCT03580993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
Study NCT03985306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inforatio technique
Description: We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment.
Study NCT05185752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIFP Block Locoregional Interfascial Anesthesic Technique
Description: Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles.
Study NCT05185752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II block: Locoregional Interfascial Anesthesic Technique
Description: Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles.
Study NCT05185752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block: Locoregional Interfascial Anesthesic Technique
Description: Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles.
Study NCT02672319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided glue injection
Description: Experimental: EUS-guided glue injection Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
Study NCT03896763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either supine or prone positioning and either CMV or HFOV
Description: Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver.
Study NCT00086515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin (MK0431)
Description: Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
Study NCT00086515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Glipizide 5 mg
Description: Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
Study NCT03987620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Ibrexafungerp 300mg BID for one day
Study NCT03987620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT00086515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
Study NCT00086515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
Study NCT00086515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
Study NCT00086515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
Study NCT02495883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ethanol
Description: 50ml of 40% Ethanol
Study NCT02495883 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol
Description: Beta blocker
Study NCT00400140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperopic lens
Description: +3 D glasses
Study NCT03539679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encouraging physical activity.
Description: Encouraging physical activity with motion sensor's feedback.